Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors

Cell Death and Disease

Volumn 3, Issue 7, 2012, Pages

  Petrini, I ^a   Meltzer, P S ^a   Zucali, P A ^b   Luo, J ^a   Lee, C ^a   Santoro, A ^b   Lee, H S ^a,c   Killian, K J ^a   Wang, Y ^a,a   Tsokos, M ^a   Roncalli, M ^b   Steinberg, S M ^a   Giaccone, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

BCL2 anti apoptotic family members; CDKN2A; comparative genomic hybridization; target therapy; thymic epithelial tumors

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; NAVITOCLAX; OBATOCLAX; PROTEIN BCL 2; SORAFENIB; ANILINE DERIVATIVE; APOPTOSIS REGULATORY PROTEIN; BCL2L2 PROTEIN, HUMAN; BENZENESULFONIC ACID DERIVATIVE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL X; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SMALL INTERFERING RNA; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE DOSAGE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; THYMIC EPITHELIAL TUMOR; THYMOMA; ALGORITHM; ANIMAL; AUTOPHAGY; COPY NUMBER VARIATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; NUDE MOUSE; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANILINE COMPOUNDS; ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BCL-X PROTEIN; BENZENESULFONATES; CELL LINE, TUMOR; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; PYRROLES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFONAMIDES; THYMUS NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84864882707     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.92     Document Type: Article

References (38)

1. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen H.J. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44: 123-130.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris C.C. Pathology and Genetics: Tumors of the Lung, Pleura, Thymus And Heart. IARC Press: Lyon, France, 2004.
3. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006; 20: 1610-1617.
4. van den Berg J, Johannsson O, Hakansson S, Olsson H, Borg A. Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. Br J Cancer 1996; 74: 1615-1619.
5. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007; 104: 20007-20012.
6. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
7. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3: 23-34.
8. Kim M, Yim SH, Cho NS, Kang SH, Ko DH, Oh B et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet Cytogenet 2009; 195: 59-65.
9. Hirose Y, Kondo K, Takizawa H, Nagao T, Nakagawa Y, Fujino H et al. Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer 2009; 64: 155-159.
10. Hirabayashi H, Fujii Y, Sakaguchi M, Tanaka H, Yoon HE, Komoto Y et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997; 73: 639-644.
11. Lal A, Kim HH, Abdelmohsen K, Kuwano Y, Pullmann Jr R, Srikantan S et al. p16(INK4a) translation suppressed by miR-24. PLoS One 2008; 3: e1864.
12. Stefanaki K, Rontogianni D, Kouvidou CH, Bolioti S, Delides G, Pantelidaki A et al. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas. Histopathology 1997; 30: 549-555.
13. Pan CC, Chen PC, Wang LS, Lee JY, Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003; 43: 165-172.
14. Khoury T, Arshad A, Bogner P, Ramnath N, Zhang S, Chandrasekhar R et al. Apoptosisrelated (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and nonreceptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms. Chest 2009; 136: 220-228.
15. Hiroshima K, Iyoda A, Toyozaki T, Supriatna Y, Shibuya K, Shimamura F et al. Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol 2002; 15: 1326-1332.
16. Chen FF, Yan JJ, Chang KC, Lai WW, Chen RM, Jin Y.T. Immunohistochemical localization of Mcl-1 and bcl-2 proteins in thymic epithelial tumours. Histopathology 1996; 29: 541-547.
17. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008; 14: 3268-3277.
18. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471: 104-109.
19. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. Small molecule obatoclax (Gx15-070) antagonizes MCL-1 and overcomes MCL-1- mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512-19517.
20. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 120: 1310-1323.
21. Espona-Fiedler M, Soto-Cerrato V, Hosseini A, Lizcano JM, Guallar V, Quesada R et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin v.s. obatoclax. Biochem Pharmacol 83: 489-496.
22. Mihaylova MM, Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13: 1016-1023.
23. Penzel R, Hoegel J, Schmitz W, Blaeker H, Morresi-Hauf A, Aulmann S et al. Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003; 105: 494-498.
24. Zettl A, Strobel P, Wagner K, Katzenberger T, Ott G, Rosenwald A et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000; 157: 257-266.
25. Inoue M, Starostik P, Zettl A, Strobel P, Schwarz S, Scaravilli F et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003; 63: 3708-3715.
26. Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009; 15: 6790-6799.
27. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
28. Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010; 116: 4686-4695.
29. Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol 6(7 Suppl 3): S1710-S1716.
30. Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004; 350: 2625-2626.
31. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov J.P. GenePattern 2.0. Nat Genet 2006; 38: 500-501.
32. Petrini I, Zucali PA, Lee HS, Pineda MA, Meltzer PS, Walter-Rodriguez B et al. Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 5(9): 1447-1453.
33. Chiarenza A, Lazarovici P, Lempereur L, Cantarella G, Bianchi A, Bernardini R. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res 2001; 61: 3002-3008.
34. Harada T, Lopez-Chavez A, Xi L, Raffeld M, Wang Y, Giaccone G. Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene 2011; 30: 1744-1745.
35. Ehemann V, Kern MA, Breinig M, Schnabel PA, Gunawan B, Schulten HJ et al. Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma. Int J Cancer 2008; 122: 2719-2725.
36. Lee JH, Voortman J, Dingemans AM, Voeller DM, Pham T, Wang Y et al. MicroRNA expression and clinical outcome of small cell lung cancer. PLoS One 6: e21300.
37. Tavecchio M, Simone M, Bernasconi S, Tognon G, Mazzini G, Erba E. Multi-parametric flow cytometric cell cycle analysis using TO-PRO-3 iodide (TP3): detailed protocols. Acta Histochem 2008; 110: 232-244.
38. Palumbo S, Toscano CD, Parente L, Weigert R, Bosetti F. The cyclooxygenase-2 pathway via the PGE(2) EP2 receptor contributes to oligodendrocytes apoptosis in cuprizoneinduced demyelination. J Neurochem 2010; 121: 418-427.